Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10147
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Read, D M | en |
dc.contributor.author | Shulkes, Arthur | en |
dc.contributor.author | Fernley, R | en |
dc.contributor.author | Simpson, R | en |
dc.date.accessioned | 2015-05-15T23:30:23Z | |
dc.date.available | 2015-05-15T23:30:23Z | |
dc.date.issued | 1991-07-08 | en |
dc.identifier.citation | Peptides; 12(4): 887-92 | en |
dc.identifier.govdoc | 1664950 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10147 | en |
dc.description.abstract | Neurotensin(6-13) has been isolated and sequenced as the major form of neurotensin-like immunoreactivity (NTLI) in a human hepatic fibrolamellar carcinoma. Circulating NTLI in the patient, especially C-terminal, was very high. In additional studies, NT(6-13) was synthesized and compared with the purified tumor NTLI by HPLC analysis and by testing stability in plasma in vitro. These methods confirmed that the tumor NTLI was identical to NT(6-13). Since the metabolic clearance rate of synthetic NT(6-13) in sheep was 30-fold higher than NT(1-13), it suggests that the elevated plasma levels are the result of impaired clearance and/or markedly elevated production. | en |
dc.language.iso | en | en |
dc.subject.other | Adult | en |
dc.subject.other | Amino Acid Sequence | en |
dc.subject.other | Animals | en |
dc.subject.other | Carcinoma, Hepatocellular.chemistry | en |
dc.subject.other | Chromatography, High Pressure Liquid | en |
dc.subject.other | Female | en |
dc.subject.other | Humans | en |
dc.subject.other | Liver Neoplasms.chemistry | en |
dc.subject.other | Molecular Sequence Data | en |
dc.subject.other | Neuropeptides.blood.chemistry.isolation & purification | en |
dc.subject.other | Radioimmunoassay | en |
dc.subject.other | Sheep | en |
dc.title | Characterization of neurotensin(6-13) from an hepatic fibrolamellar carcinoma. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Peptides | en |
dc.identifier.affiliation | Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia | en |
dc.description.pages | 887-92 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/1664950 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.